LLY vs MS: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Morgan Stanley · Financial Services
$206.27
+15.9% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MS has more upside to fair value
(+15.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
MS |
| Current Price |
$1,183.72 |
$206.27 |
| Fair Value Estimate |
$1,208.00 |
$239.00 |
| Upside to Fair Value |
+2.1%
|
+15.9%
|
| Market Cap |
$1,114.8B |
$325.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
23.5x
|
| Price / Sales |
14.0x
|
2.6x
|
| Price / FCF |
52.7x
|
—
|
| Revenue Growth YoY |
+47.7%
|
+22.4%
|
| Gross Margin |
83.4%
|
59.7%
|
| Operating Margin |
49.7%
|
20.7%
|
| Return on Equity |
92.6%
|
18.1%
|
| Dividend Yield |
0.57% |
2.01% |
| FCF Yield |
1.9%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Morgan Stanley is a diversified capital-markets and wealth-management franchise spanning institutional securities, advisor-led and self-directed wealth, workplace services, and investment management. Business quality is solid but inherently cyclical: it combines $8.084 trillion of wealth client assets and $2.004 trillion of investment-management AUM/AUS with a strengthening 15.5% institutional pe…
Accumulation Zones
| Metric |
LLY |
MS |
| Zone Low |
$906.00 |
$179.25 |
| Zone High |
$1,026.80 |
$203.15 |
| In Buy Zone? |
No
|
No
|